SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin’s arm launches Luforbec in Germany

21 Jul 2023 Evaluate

Lupin’s wholly-owned subsidiary -- Hormosan Pharma GmbH (Hormosan) has launch Luforbec 100/6 (beclometasone 100 µg / formoterol 6 µg), a fix combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany. 

Luforbec 100µg/6µg pMDI is indicated for adult asthma and COPD treatment, where the use of an inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA) is suitable. With the same active ingredients as Foster 100/6 pMDI and an extra fine formulation, Luforbec offers the same licensed indications and similar device characteristics. Luforbec pMDI provide significant cost savings, priced at - 47% below the fixed reference price on the pharmacy selling price.

With a significant portion of the population (5% of adults and 10% of children) currently undergoing asthma treatment, Luforbec 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals. This launch reflects Lupin’s unwavering commitment to addressing the critical needs of asthma management in Germany. 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×